ACETAMINOPHEN TOXICITY DIAGNOSTICS, LLC — Department of Health and Human Services SBIR Phase II: 300
ACETAMINOPHEN TOXICITY DIAGNOSTICS, LLC — SBIR Phase II award from Department of Health and Human Services.
Phase II SBIR prototype / development signal
- Phase II is where Department of Health and Human Services funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- At $2,391,840, this is a large obligation for typical SBIR Phase sizing — worth reviewing for scope breadth and teaming opportunity.
- Topic code 300 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $2,391,840
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- Topic
- 300
- Solicitation
- PA20-272
- NAICS
- —
- Place of performance
- AR
- Period
- 2022-04-15 → 2025-03-31
Description
James, Laura P Project Summary/Abstract The original plan for development of AcetaSTAT was to use banked samples of serum collected from acetaminophen overdose patients to verify the effectiveness of the assay prior to verification and validation efforts. However, during the development of the work it has become apparent that banked samples cannot be used due to their instability and repeated exposure to freezing and re- thawing of samples. The assay is intended for immediate use by the clinician, so although it appears to be sensitive to sample age, this will not impact the final intended use. However, the lack of more recent samples has delayed the project and we have determined it will be necessary to collect fresh samples from patients with acetaminophen exposure.